of donor myoblasts is understood and overcome, in order for MTT to be successful in potential clinical situations.
Activation of the complement cascade is one possible mechanism that could account for the initial, very rapid death of the donor myoblasts. This system consists of many complex proteins that form a proteolytic cleavage cascade (reviewed in Carroll 19 ), that ultimately results in target cell lysis via the generation of a membrane attack complex (MAC) that can lyse target cells extremely rapidly and is active for less than one second 20 (see Fig. 1 ). Complement activation is involved in the initiation of an inflammatory response to reperfusion of ischaemic skeletal muscle, 21 occurs in damaged muscle fibres in certain myopathies, [22] [23] [24] [25] [26] [27] as well as after bupiviacaine-induced necrosis in vivo, 28 and cultured myoblasts have been shown to fix complement in vitro. 29 While one study has investigated the potential role of complement in MTT, 30 the extent of donor myoblast death was not quantified. The present study was designed to quantify the survival of male donor myoblasts after injection into host mice where the complement response was prevented using two strategies; cobra venom factor (that depletes C3) and the use of C5-deficient (DBA-2) host mice. 31, 32 Cobra venom factor (CVF) is a well-characterized anticomplement glycoprotein (reviewed in Vogel and MullerEberhard 33, 34 ), that has a C3/C5 convertase activity that rapidly depletes the host's C3 component by activation and conversion, 35 making CVF an effective compound to deplete animals of C3 (see Fig. 1 ). Cobra venom factor modifies hyperacute xenograft rejection in the discordant guinea pig to Lewis rat cardiac xenograft model 36 and delayed-type hypersensitivity reactions in mice. 37 Quantitative analyses (using the male-specific Y1 probe) of donor (male) myoblast survival after injection into (female) normal C57BL/10Sn and DBA-1 host mice (the parental strain of DBA-2) depleted of complement component C3 using CVF, as well as in C5-deficient (DBA-2) host mice are presented here.
Materials and Methods

Animals
C57BL/10Sn, DBA-1 and DBA-2 were obtained from the Animal Resource Centre, Murdoch, Western Australia. All animal procedures were carried out in strict accordance with National Health and Medical Research Council of Australia guidelines and with approval from the Animal Ethics Committee of the University of Western Australia.
Tissue culture
Skeletal muscles were taken from the hind limbs and lower back of 4-6-week-old donor male C57BL/10Sn or DBA-1 mice. Myoblasts were isolated from these muscles by enzymic digestion and filtration through 100 µm nylon gauze as described previously. 2, 9 The resulting primary culture was maintained in Hams F10 medium (Trace, Castle Hill, NSW, Australia) supplemented with 20% (v/v) FCS (Trace), 4 mmol/L L-Glutamine (Sigma, St Louis, MO, USA), 100 IU/mL Penicillin, 100 µg/mL Streptomycin (Sigma) and 25 ng/mL basic fibroblast growth factor (bFGF) (Sigma). Medium was replaced every other day and cells were grown to 70-80% confluency before harvesting by digestion with 0.1% (w/v) trypsin (ICN-Flow). Cells were reseeded at approximately 1-2 × 10 5 cells per 75 cm 2 flask (precoated with 1% (w/v) gelatin) in fresh medium and passaged successively in this way.
Myoblast injection
Male C57BL/10Sn and DBA-1 primary myoblast cultures were harvested using trypsin/EDTA, adjusted to a concentration of 2.5 × 10 5 /10 µL in endotoxin-tested PBS (pH 7.2) and the cells kept on ice until injected. Ten microlitres of this cell suspension was injected longitudinally into each tibialis anterior (TA) of 6-8-weekold female host mice using a Hamilton syringe with a 29G needle. The needle was retracted carefully as the cells were injected in order to minimize the physical trauma of the procedure. Host mice used for 0 h time points were injected after surgically exposing the TA muscle, so that the sample was ready for immediate removal. Control mice were injected with 10 µL of endotoxin-tested sterile PBS (Trace). Female host mice (C57BL/10Sn, DBA-1 and C5-deficient DBA-2) were killed at 0 h, 1 h, 24 h, 1 week and 3 weeks after myoblast injection and TA muscles were isolated. Samples were used for DNA quantification, and separate representative TA samples were used for the generation of frozen sections for immunohistochemistry. Control (no PBS, no MTT, as well as PBS injected) TA muscles, were also taken.
C3 depletion using cobra venom factor
Host mice were depleted of C3 with a single i.p. injection of 100 µL (25 mg) of CVF (Venom Supplies, Tanunda, SA, Australia), 24 h prior to MTT. This is the time required for systemic C3 depletion. Host mice were then subjected to MTT as described. Serum samples of control and depleted host mice were also taken at 0 h, 1 h, 24 h, 1 week and 3 weeks after MTT and stored at 4°C before assaying for circulating C3 complement levels. Serum samples were taken via cardiac bleed immediately after removal of the TA muscle.
Complement (C3) detection
Circulating C3 in serum samples were analysed using double immunodiffusion. Briefly, the presence and/or absence of C3 component in serum samples taken from control (PBS-injected), as well as CVF-treated and untreated (no CVF) host mice at 0 h, 1 h, 24 h, 1 week and 3 weeks following MTT was detected by the formation of precipitation arcs in 1% (w/v) agarose using a goat antiserum to mouse complement C3 (ICN/Cappel, Costa Mesa, CA, USA). Equal volumes of antigen (serum) and antibody were added to wells and left overnight at 4°C. Precipitation arcs were clearly visible between antigen and antibody wells and photographed using oblique light or further visualized by staining with 1% (w/v) Coomassie Brilliant Blue.
C3 immunohistochemistry
Frozen sections of whole representative TA muscles taken at 0 h, 1 h, 24 h, 1 week and 3 weeks after MTT, as well as 'PBS-injected' controls and 'no PBS, no MTT' controls were immunostained for the presence and location of C3 using a goat antiserum to mouse complement C3 (ICN/Cappel, USA) at 1/200 dilution, followed by a donkey antigoat Alexa 488 conjugated secondary antibody (Molecular Probes, Eugene, OR, USA) at 1/1000 dilution. Briefly, sections were rehydrated in a small volume of PBS, and blocked using 10% (v/v)/FCS/1% (w/v) BSA in PBS for 30 min at room temperature. Incubation with primary antibody was performed overnight at 4°C. Sections were washed three times in PBS and incubated with secondary antibody overnight at 4°C. After washing briefly with PBS, sections were mounted using DPX (BDH Laboratory Supplies, Poole, UK) and examined.
Quantification of DNA from male donor myoblasts
Female host mice (C57BL/10Sn, DBA-1 and C5-deficient DBA-2) were killed at 0 h, 1 h, 24 h, 1 week and 3 weeks after MTT and TA muscles isolated. Each muscle was cut into 2-3 mm 3 pieces and then homogenized in DNA isolation buffer (50 mmol/L Tris-HCl, 150 mmol/L NaCl, 2 mmol/L EDTA (pH 8)) using an Ultra-Turrax homogeniser (Janke and Kunkel, Staufen, Germany). After adding SDS to a final concentration of 0.2% (w/v) and incubating at 65°C for 20 min, Proteinase K (Boehringer Mannheim, Mannheim, Germany) was added to a final concentration of 200 µg/mL and the samples incubated overnight at 37°C. Samples were extracted once in phenol (Tris-HCl buffered, pH 7.4-7.9) (Gibco BRL, Rockville, MD, USA), once in 25:24:1 phenol : chloroform : isoamyl alcohol, once in 24:1 chloroform : isoamyl alcohol and then ethanol precipitated overnight at -20°C. Deoxyribonucleic acid pellets were resuspended in double distilled water overnight at 4°C and quantified by measuring the absorbance at 260/280 nm. Deoxyribonucleic acid integrity was also checked visually under UV illumination after electrophoresis in 1% (w/v) agarose in the presence of ethidium bromide. The remainder of the DNA was applied to Hybond-N+ nylon membrane (Amersham, Little Chalfont, UK) using a slot-blot apparatus (Bio Rad, Hercules, CA, USA) according to the manufacturer's instructions. Donor male DNA was quantified by hybridization with the Y-chromosome specific Y1 probe, 7-9 which was random prime-labelled using α 32 P dCTP (DuPoint, Boston, MA, USA). Dilutions of Y1 were applied to each slot blot as a standard positive control, as well as control samples of 2.5 × 10 5 male donor myoblasts (in triplicate), designated as 100%. Quantification was performed by densitometric analysis after exposure to phosphorimaging screens (Fuji, Osaka, Japan) using a MacBas 2500 phosphorimaging system (FujiFilm) and Image Reader 1.5E/Image Gauge V3.0 software. Statistical analysis of quantitative DNA data was performed using Minitab software (Minitab Inc., State College, PA, USA).
Results
Levels of C3 complement
Serum samples collected from C57BL/10Sn, DBA-1 and DBA-2 host mice that were either control (PBS-injected, no MTT), untreated (no CVF prior to MTT) or CVF-treated (C3 depleted, 24 h prior to MTT) were subjected to double immunodiffusion assays in order to determine the presence and/or absence of circulating C3 (Fig. 2) . Sera from control C57BL/10Sn, DBA-1 and DBA-2 host mice contains circulating C3 (well 1, Fig. 2a-c) as indicated by comparable precipitation arcs. The presence of C3, as indicated by precipitation arcs, in all untreated (non-CVF, MTT) host mice at 0 h, 1 h, 24 h, 1 week and 3 weeks following MTT, were similar to that detected in control (PBS-injected, no MTT) mice (Fig. 2a, wells 2-6 , respectively). C3 was undetectable in CVF-treated host mice at 0 h, 1 h and 24 h after MTT, as indicated by the absence of precipitation arcs (Fig. 2b,c , wells 2-4, respectively). C3 was detectable in the serum of all CVF-treated host mice at 1 week after MTT (Fig. 2b,c , well 5) and by 3 weeks (Fig. 2b,c, well 6 ) was comparable to C3 detected in control mice (Fig. 2a) . Note that Fig. 2 shows results for C57BL/10Sn and DBA-1 host mice only, although detection of C3 for each treatment was the same for DBA-2 mice (data not shown).
DNA quantification of surviving donor male myoblasts
The amount of surviving donor male (Y1 positive) myoblast DNA recovered from injected female host TA muscles was quantified by calculating the percentage of radioactive 32 P signal compared to that obtained from Y1 hybridization to 2.5 × 10 5 cultured donor male myoblasts (designated as 100%). 9 
Untreated and CVF-treated C57BL/10Sn host mice
Quantification of male DNA on slot blots using the Y1 probe showed a characteristically rapid and massive loss of male DNA after injection of normal C57BL/10Sn donor male myoblasts into untreated C57BL/10Sn female host mice. 9 An average of only approximately 10% of donor cells survived at 0 h (2-5 min after injection) and numbers of donor cells declined over time such that by 3 weeks (504 h) only approximately 2% of donor myoblasts were present (Fig. 3a) . A twofold increase at 0 h (to approximately 20%) was seen in the average survival of C57BL/10Sn donor myoblasts after myoblast injection into CVF-treated C57BL/10Sn hosts and these donor myoblasts persisted for at least 24 h. Numbers of donor myoblasts declined over 1 week (168 h), although at 3 weeks (504 h) there were still significantly more (threefold) donor myoblasts than in untreated C57BL/10Sn hosts. ANOVA showed statistically significant differences (P < 0.005) in the average number of C57BL/10Sn donor myoblasts at each time point after injection between untreated and CVF-treated C57BL/10Sn host mice.
Untreated and CVF-treated DBA-1 host mice
A similar rapid and massive loss of male DNA was seen after injection of normal DBA-1 donor male myoblasts into untreated DBA-1 female host mice (Fig. 3b) . However, there was a marked strain specific difference as the initial number of donor myoblasts surviving in DBA-1 hosts was more than double that seen with C57BL/10Sn hosts. Approximately 40% of the injected donor myoblasts survived in DBA-1 mice at 0 h (compared with approximately 20% in C57BL/10Sn hosts -see also Hodgetts et al. 9 ). This rapidly declined to 10% at 1 h and by 3 weeks only approximately 5% of donor myoblasts were present. The average survival of donor myoblasts was significantly increased in CVF-treated DBA-1 hosts (compared to untreated DBA-1 hosts), over the first week. At 1 h, approximately 85% of donor myoblasts had survived (nearly eightfold over untreated DBA-1 host mice). By 1 week there were still significantly more myoblasts in CVF-treated hosts, although numbers gradually declined. By 3 weeks only approximately 5% of donor myoblasts remained and this value was not different from untreated DBA-1 hosts. ANOVA showed statistically significant differences (P < 0.005) in the average numbers of donor myoblasts at 1 h, 24 h and 1 week after injection between untreated and CVF-treated DBA-1 host mice.
Untreated and CVF-treated DBA-2 host mice
At 0 h after MTT only approximately 10% of injected DBA-1 donor myoblasts remained in untreated DBA-2 female hosts (Fig. 3c) . Over time this value declined so that by 3 weeks only approximately 5% of donor myoblasts were present. Apart from time 0, all average survival values were similar to those in untreated DBA-1 hosts. In CVF-treated DBA-2 hosts (i.e. C3 depleted and C5 deficient), there was a marked increase in the average number of donor myoblasts at each time point (compared to untreated DBA-2 hosts), although the percentage continued to decline over 1 week. At 0 h approximately 60% of the injected donor cells had survived (sixfold over untreated DBA-2 hosts at 0 h). The average percentage of surviving donor myoblasts declined over time, and by 24 h was comparable to that observed in untreated DBA-2 hosts. ANOVA showed statistically significant differences (P < 0.005) in the average number of donor myoblasts immediately after, 1 h and at 1 week following MTT between untreated and CVF-treated DBA-2 host mice.
The data for all three strains presented in Fig. 3a -c are summarized in Fig. 4 to compare the average survival of donor male myoblasts between strains following injection into untreated (a) and CVF-treated (b) hosts. (Fig. 5a ) and a pronounced C3 staining around the myofibers of control (PBSinjected) muscles (Fig. 5b) . Following MTT, such C3 staining was also visible in untreated TA muscles taken at 0 h (Fig. 5c ) and 24 h (Fig. 5e ). Blood vessels were strongly stained for C3 in sections from untreated hosts. In marked contrast, in CVFtreated TA muscles there was no C3 staining around the myofibers at 0 h (Fig. 5d) or 24 h (Fig. 5f ) after MTT. There was some weak, irregular staining of isolated areas of myofiber membranes (Fig. 5d,f) , possibly indicating that C3 depletion was not complete locally within the TA following CVF treatment. Some immunosections showed injected donor (male) myoblasts that were positive for C3 staining (mainly intracellular), even at 0 h after MTT (data not shown).
Immunohistochemistry
Discussion
The very rapid death of donor myoblasts [1] [2] [3] [4] [5] [6] 9 is difficult to explain. Clearly, an effector mechanism, such as complement, that is capable of rapid and widespread cell death must be involved in the process. For this reason we quantitatively assessed (using the Y-chromosome specific probe) the effect of complement depletion on the survival of cultured male donor myoblasts immediately following (and up to 3 weeks after), their injection into TA muscles of female host mice.
Depletion of host complement C3 using cobra venom factor
Prior to assessing the impact of host complement C3 depletion on the success of MTT, the amount of C3 remaining in serum and skeletal muscles was examined using immunodiffusion and western blotting. Circulating C3 was effectively depleted after CVF-treatment in all strains of mice for up to 48 h (Fig. 2) . At 1 week after MTT, circulating C3 was similar to that of control mice, indicating that the effect of a single CVF depletion (prior to MTT) is only transiently effective at depleting C3. While differences in the concentrations of serum 38 and in allotypic forms of C3 39 between strains have been reported, the control (untreated) C57BL/10Sn, DBA-1 and DBA-2 mice showed similar C3 sera 'levels' in the present study, as detected visually by immunodiffusion.
Data from immunohistochemical staining of frozen TA sections in these host mice suggest that, although circulating C3 was effectively depleted, extremely low amounts of localized C3 component were still present in the skeletal muscle of CVF-treated mice (Fig. 5d,f) . Immunosections showed that myoblasts were positive for C3 staining (mainly intracellular), even at 0 h after injection, suggesting that complement fixation rapidly occurred at the injection site following MTT. This result is in accord with the observations of Skuk and Tremblay 30 who also showed transplanted immortalized donor myoblasts that had fixed complement. The strong C3 staining in control (PBS injected, Fig. 5b ) host muscles suggests that the physical process of injection itself may be responsible for C3 fixation in host muscle, especially when one considers the weak staining observed in untreated controls (no PBS, no MTT, Fig. 5a ). It is unlikely that sterile PBS Complement and myoblast transfer therapy 235 would activate the complement cascade, especially as endotoxin-tested PBS was used in this study, although no animals were subjected to needle insertion without injection. The limit of detection of C3 could be more sensitive on immunosections than in double immunodiffusion plates and it is possible that any recovery of C3 component has not yet reached the level of detectability using double immunodiffusion. Indeed, Skuk and Tremblay reported that CVF-treated host mice subjected to MTT showed 'very slight or absent' C3 staining on sections of muscle immediately following MTT. 30 Sewry et al. 25 also indicated that there may be a discrepancy between the levels of complement detectable in circulating serum, as compared to complement localized in specific tissues.
DNA quantification of surviving donor myoblasts
The percentage of donor male myoblasts surviving after injection into untreated C57BL/10Sn, DBA-1 and C5-deficient DBA-2 host mice (Fig. 4a) shows a classical 'death curve' compared to that obtained in a previous report . 9 There was a characteristically rapid and massive death of cultured male donor myoblasts within minutes of injection into all three strains, and survival declined further over 3 weeks to within 5-10%, as has been described previously for C57BL/10Sn and mdx host mice. 1, 2, 4, 5, 9 While the overall trend was similar for C57BL/10Sn, DBA-1 and DBA-2 mice there were significant strain-specific differences in the initial numbers of surviving donor myoblasts. These data suggest that there may be some variation in the survival of donor myoblasts between strains of host mice used.
Further differences in early myoblast survival between strains were noted in host mice treated with CVF. Deoxyribonucleic acid quantification data using the Y1 probe reveals that host depletion of C3 (or decomplementation) increased the average percentage of surviving donor male myoblasts twofold (to approximately 20%) in CVF-treated C57BL/10Sn host mice (Fig. 3) , and that this survival was maintained over 1 week. Donor myoblast survival in CVF-treated DBA-1 and DBA-2 mice was significantly higher immediately after MTT. The number of donor myoblasts remained high (at approximately 85-90%) in DBA-1 mice at 1 h. After 1 h all strains showed a similar progressive 'death curve' and myoblast numbers at 3 weeks were similar (less than 10%) in all three strains. The reasons for these differences in donor myoblast survival in different strains of CVF-treated mice within the first 24 h after MTT are not known, but they emphasize that genetic factors can influence the success of MTT. Despite these differences, the effect of C3 decomplementation by CVF does suggest a role for C3 in the death of donor myoblasts following MTT. The loss of this beneficial effect after 3 weeks is expected given that a single C3 depletion using CVF is only temporary.
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Our quantitative data clearly demonstrate a role for C3 in donor myoblast death and contrast markedly with the conclusions of the study by Skuk and Tremblay. 30 The rapid death of donor myoblasts in untreated DBA-2 mice shows that a lack of complement C5 makes no difference to donor myoblast survival. C5-deficient mice suffer a deletion in the gene encoding functional C5 so that the mRNA codes for an abnormal protein 31, 32, 40 and the rest of the complement cascade are blocked. One report suggests that C5 fragments are important in polymorphonuclear leucocyte accumulation at inflammatory sites in both C5-sufficient and C5-deficient strains of mice. 41 Our results indicate that the full complement cascade per se, and especially C5b-C9, does not play a central role in the rapid death of myoblasts. Skuk and Tremblay also reported little evidence of MAC formation following MTT in CVF-treated host mice. 30 The existence of functional C3a/C5a fragments in C5-deficient mice, as well as opsonic C3b/C3bi molecules, may be involved in the generation of peptides that are chemotactic for neutrophils and NK cells, which are thought to be involved in the death of donor myoblasts following MTT. 9, 30, 42, 43 Recent studies in our laboratory emphasize a key role for NK cells in donor myoblast survival (SI Hodgetts and MD Grounds, unpubl. data, 2001 ). However, the removal of C3 complement with CVF did result in significantly enhanced donor myoblast survival following MTT. These data could be explained if C3 were normally involved in donor myoblast death without the need for C5. In addition, a more general immunosuppressive effect of CVF resulting from the generation of complement cleavage products, may also impair the secretory functions and activation states of immune cells, such as macrophages, and their subsequent contribution to humoral (T-cell dependent) responses. [44] [45] [46] While the mechanism underlying the protective effect of CVF is unclear, the influence was only transitory as evidenced by generally similar numbers of myoblasts at 3 weeks in CVF treated and control muscles.
Exposure to tissue culture prior to transplantation in vivo can adversely affect the donor myoblasts.
14 It is possible that culture conditions may reduce expression of regulatory proteins [such as Crry, CD59, decay accelerating factor (CD55) or membrane cofactor protein (CD46)] on myoblasts that inhibit complement activation (reviewed in Nangaku 47 ). Expression of such regulatory proteins has been shown to protect cells from complement mediated injury. [48] [49] [50] [51] [52] In addition, activated C3a/C3b fragments are generated from native C3 following treatment with trypsin, 53 which is used in the regular passaging of cells in culture. Further work is required to address the role of such complement regulatory proteins in the death of donor myoblasts in MTT after exposure to tissue culture conditions (including trypsin). The use of primary myoblasts (as in the present study) to test regimes such as complement depletion, as opposed to the use of immortalized clones of donor myoblasts (as used in Skuk and Tremblay 30 ), are important to confirm the potential relevance to clinical MTT. The 'only transient' benefit of regimes such as CVF treatment on MTT highlight the multifactorial processes that are probably involved in the death of cultured donor myoblasts in the in vivo environment. Identification of the cellular events involved in these early events is of critical importance, in order to develop strategies to enhance longterm survival of donor myoblasts in MTT.
